Sugi Predict

Sugi Predict / Compounds / SCHEMBL14901243

SCHEMBL14901243

SCHEMBL14901243

COc1cc(OC)c(Cl)c(Nc2ccc3ncc(-c4cnn(C)c4)nc3n2)c1Cl

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.52
▸ PIK3CA P42336 1/20 0.52
▸ MAPK8 P45983 1/20 0.52
▸ MAPK9 P45984 1/20 0.52
▸ MAPK10 P53779 1/20 0.52
▸ FGFR3 P22607 19/20 0.51
▸ FGFR1 P11362 13/20 0.51
▸ FGFR2 P21802 13/20 0.51
▸ KDR P35968 12/20 0.51
▸ FGFR4 P22455 11/20 0.51
▸ FLT3 P36888 4/20 0.51
▸ VEGFA P15692 1/20 0.46
▸ FLT1 P17948 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14901157 0.90 MAPK1 (0.50) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL14901242 0.89 MAPK1 (0.48) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL14901179 0.88 FGFR3 (0.54) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL14901141 0.87 FGFR3 (0.54) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL14905397 0.84 FGFR3 (0.59) MAPK1FGFR3FGFR1FGFR2KDR
SCHEMBL19749891 0.83 FGFR3 (0.68) FGFR3FGFR1FGFR2KDRFGFR4
SCHEMBL14901120 0.81 FGFR3 (0.54) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL14901222 0.80 FGFR3 (0.55) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL14901123 0.79 MAPK1 (0.55) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL14901142 0.78 MAPK1 (0.56) MAPK1PIK3CAMAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776435-B1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES ASTEX THERAPEUTICS LTD (GB) 2018-06-27 — — EP disclosed
US-10004733-B2 — — 2018-06-26 — — US disclosed
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2016-08-18 — — US disclosed
US-9309242-B2 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2016-04-12 — — US disclosed
US-20140288053-A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES ASTEX THERAPEUTICS LIMITED (GB) 2014-09-25 — — US disclosed
WO-2013061080-A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES ASTEX THERAPEUTICS LIMITED (GB) 2013-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10004733-B2 — SDHB, SDHA, NDUFS5 MAPK1 2681/4885PIK3CA 580/4885MAPK8 3344/4885
US-20140288053-A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES FGFR1, FGFR2, FGFR4 MAPK1 322/4885PIK3CA 83/4885MAPK8 511/4885
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS FGFR1, FGFR2, FGFR3 MAPK1 333/4885PIK3CA 55/4885MAPK8 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.